M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
The average takeout premium for a research-stage biotech is tracking at 100% this year, the latest data show.
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
Device deal making is back in a big way, despite the munificence of venture funds.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
The first quarter of 2021 saw fewer deals than any in recent memory.
It takes more than a pandemic to stop medical device companies merging.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.